Advanced Micronized Chelation Technology™
A next-generation oral delivery platform for GLP-1 receptor agonists and peptide biologics. AMCT™ replaces gastric disruption with controlled, biologically aligned transport mechanisms.
~200×
Lower API Dose vs. SNAC
180+ days
Sustained Observational Data
0.05–0.35 mg
Observed Daily GLP-1 Range
No fasting
Administration Requirement
Safety & Tolerability Profile
Unlike gastric pH-altering or membrane-irritating excipient systems, AMCT™ is designed to preserve epithelial integrity and physiologic function. Observational use has demonstrated no gastric mucosal injury, no clinically meaningful epithelial barrier disruption, and no dose-limiting GI toxicity attributable to the delivery system.
No Gastric Irritation
No mucosal injury attributed to delivery system
No Serious AEs
No serious adverse events observed to date
Consistent GLP-1 Profile
AEs consistent with known GLP-1 class, not delivery-specific
| System Organ Class | Adverse Event | Severity | Frequency | Duration / Resolution |
|---|---|---|---|---|
| Gastrointestinal | Nausea | Mild | Occasional | Transient; resolved without intervention |
| Gastrointestinal | Early satiety / appetite suppression | Mild | Common | Persistent during active therapy |
| Gastrointestinal | Abdominal discomfort | Mild | Infrequent | Self-limited |
| Gastrointestinal | Vomiting | None observed | — | — |
| Gastrointestinal | Diarrhea | None observed | — | — |
| Metabolic | Hypoglycemia | None observed† | — | — |
| Nervous system | Headache | Mild | Infrequent | Transient |
| General disorders | Fatigue | Mild | Infrequent | Transient |
| Cardiovascular | Clinically significant events | None observed | — | — |
| Hepatic | Clinically significant abnormalities | None observed | — | — |
| Renal / Urinary | Clinically significant abnormalities | None observed | — | — |
† No hypoglycemia observed; consistent with GLP-1 class. Data from limited non-randomized observational use. Not intended to establish incidence rates or comparative safety.
Educational reference only. For licensed prescribers. No claims of bioequivalence or therapeutic equivalence. All prescribing decisions remain with the treating clinician. Confidential — not for patient distribution. Source: AMCT™ Whitepaper Version 2.0, Updated February 2026 · Zoom Biotech / Village Compounding Pharmacy Partnership.